Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsDe Rycker, Manu
Amewu, Richard K
Barry, Clifton E
Buckner, Frederick S
Ferguson, Michael A J
Lafuente-Monasterio, Maria Jose
Leeson, Paul D
Manjunatha, Ujjini H
Miles, Timothy J
Overington, John P
Rao, Srinivasa P S
Read, Kevin D
Silver, Lynn L
Van Voorhis, Wes
White, Nicholas J
Wyatt, Paul G
Gilbert, Ian H
MetadataShow full item record
AbstractIn May 2019, the Wellcome Centre for Anti-Infectives Research (WCAIR) at the University of Dundee, UK, held an international conference with the aim of discussing some key questions around discovering new medicines for infectious diseases and a particular focus on diseases affecting Low and Middle Income Countries. There is an urgent need for new drugs to treat most infectious diseases. We were keen to see if there were lessons that we could learn across different disease areas and between the preclinical and clinical phases with the aim of exploring how we can improve and speed up the drug discovery, translational, and clinical development processes. We started with an introductory session on the current situation and then worked backward from clinical development to combination therapy, pharmacokinetic/pharmacodynamic (PK/PD) studies, drug discovery pathways, and new starting points and targets. This Viewpoint aims to capture some of the learnings.
CitationACS Infect Dis. 2019 Dec 6. doi: 10.1021/acsinfecdis.9b00371.
AffiliationHIPS, Helmholtz-Institut für Pharmazeutische Forschung Saarland, Universitätscampus E8.1 66123 Saarbrücken, Germany.
PublisherAmerican Society for Chemistry
JournalACS Infectious Diseases
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International
- [Development of antituberculous drugs: current status and future prospects].
- Authors: Tomioka H, Namba K
- Issue date: 2006 Dec
- Macromolecular crowding: chemistry and physics meet biology (Ascona, Switzerland, 10-14 June 2012).
- Authors: Foffi G, Pastore A, Piazza F, Temussi PA
- Issue date: 2013 Aug
- Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research.
- Authors: Tuntland T, Ethell B, Kosaka T, Blasco F, Zang RX, Jain M, Gould T, Hoffmaster K
- Issue date: 2014
- Current status and future perspective on preclinical pharmacokinetic and pharmacodynamic (PK/PD) analysis: Survey in Japan pharmaceutical manufacturers association (JPMA).
- Authors: Goto A, Abe S, Koshiba S, Yamaguchi K, Sato N, Kurahashi Y
- Issue date: 2019 Apr
- Japan-China Joint Medical Workshop on Drug Discoveries and Therapeutics 2008: The need of Asian pharmaceutical researchers' cooperation.
- Authors: Nakata M, Tang W
- Issue date: 2008 Oct